HK1257679A1 - 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 - Google Patents

使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 Download PDF

Info

Publication number
HK1257679A1
HK1257679A1 HK19100043.6A HK19100043A HK1257679A1 HK 1257679 A1 HK1257679 A1 HK 1257679A1 HK 19100043 A HK19100043 A HK 19100043A HK 1257679 A1 HK1257679 A1 HK 1257679A1
Authority
HK
Hong Kong
Prior art keywords
phenylbutyrate
phenylacetate
ornithine
combination
neuronal cell
Prior art date
Application number
HK19100043.6A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher F. ROSE
Marc-André CLÉMENT
Cristina R. BOSOI
Mariana Macedo OLIVEIRA
Mélanie TREMBLAY
Chantal BÉMEUR
Original Assignee
Ocera Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics, Inc. filed Critical Ocera Therapeutics, Inc.
Publication of HK1257679A1 publication Critical patent/HK1257679A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK19100043.6A 2015-09-25 2016-09-22 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 HK1257679A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US201562233002P 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (1)

Publication Number Publication Date
HK1257679A1 true HK1257679A1 (zh) 2019-10-25

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100043.6A HK1257679A1 (zh) 2015-09-25 2016-09-22 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失

Country Status (7)

Country Link
US (1) US20200206174A1 (cg-RX-API-DMAC7.html)
EP (1) EP3352748A4 (cg-RX-API-DMAC7.html)
JP (1) JP6989495B2 (cg-RX-API-DMAC7.html)
AU (1) AU2016325556B2 (cg-RX-API-DMAC7.html)
CA (1) CA2998490A1 (cg-RX-API-DMAC7.html)
HK (1) HK1257679A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017053613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
NZ732632A (en) 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
CA3100944A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
JP2022533569A (ja) * 2019-05-09 2022-07-25 オセラ セラピューティクス， インコーポレイテッド 肝性脳症を評価および処置する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
PT2153870E (pt) * 2004-11-26 2014-03-12 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
NZ708458A (en) 2009-04-03 2017-02-24 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
EA025735B1 (ru) * 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата

Also Published As

Publication number Publication date
WO2017053613A8 (en) 2017-04-27
JP2018531929A (ja) 2018-11-01
WO2017053613A1 (en) 2017-03-30
EP3352748A4 (en) 2019-06-05
AU2016325556A1 (en) 2018-03-01
US20200206174A1 (en) 2020-07-02
JP6989495B2 (ja) 2022-01-05
CA2998490A1 (en) 2017-03-30
EP3352748A1 (en) 2018-08-01
AU2016325556B2 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
HK1257679A1 (zh) 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
USD824028S1 (en) Radiofrequency treatment probe for treating vaginal laxity
MX2018002320A (es) Abrazaderas quirurgicas de diseccion.
HK1246151A1 (zh) 为t细胞疗法而调理患者的方法
WO2016037138A8 (en) Globin gene therapy for treating hemoglobinopathies
AU2015214400B2 (en) Self-priming systems and methods
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
EP3331459A4 (en) DEVICES, SYSTEMS, AND METHODS OF COLLECTION FOR USE IN BONE TISSUE
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
EP3520395A4 (en) OPTICAL SYSTEMS FOR SURGICAL PROBES, SYSTEMS AND METHODS THEREFOR AND METHOD FOR CARRYING OUT SURGICAL INTERVENTIONS
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
EP3434170A4 (en) ENDOSCOPE DEVICE, ENDOSCOPE SYSTEM, AND SURGICAL SYSTEM THEREFOR
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
EP3370633A4 (en) ORTHOPEDIC FASTENER, HOLDER AND GUIDANCE
WO2016055797A3 (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
EP3745967A4 (en) DEVICES AND METHODS FOR TREATMENT OF BLOCKED BLOOD VESSELS
MX2025006207A (es) Composiciones que contienen arginasa i humana con un cofactor de metal de cobalto para usarse en el tratamiento de la deficiencia de arginasa 1
HK1258276A1 (zh) 用於治疗hiv的化合物和组合
WO2016102930A3 (en) Medical device for treating a vein
WO2015085314A3 (en) Methods for detection of heart failure
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2016044093A3 (en) Aeration discs and methods for using same
WO2013138338A3 (en) Methods for treating tissue damage associated with ischemia with apoliporotein d
WO2019118484A3 (en) Multi-use endoscopes and associated systems and methods